Goulart, Bernardo <br/><br/>
A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.  [electronic resource] 

 -  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research   
 - 836-45 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1524-4733 
<br/><br/><label>Standard No.: </label>10.1016/j.jval.2011.04.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--economics<br/>Antibodies, Monoclonal--economics<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--economics<br/>Bevacizumab<br/>Carboplatin--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Clinical Trials as Topic<br/>Cost-Benefit Analysis<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Markov Chains<br/>Paclitaxel--administration & dosage<br/>Quality-Adjusted Life Years